Press Releases

Biogen and Eisai, Co., Ltd. announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer's disease. Aducanumab, an amyloid beta-targeting antibody, has been shown in clinical trials to remove amyloid beta in the brain and significantly slow clinical decline in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and mild Alzheimer's diseas

Gilead Sciences, Inc. and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million (both payments subject to customar

Boehringer Ingelheim announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk & Kollegen has outstanding experience in process development, manufacturing

Tobin Scientific and PHCbi have announced a collaboration that is designed to address the unique transportation requirements of one of the lead COVID-19 vaccines. The solution uses Tobin trailers fitted with PHCbi’s ultra-low temperature freezers to ensure that the vaccine is maintained at the correct temperature throughout transit. Following the announcement last week that Pfizer and partner, BioNTech, had submitted an application to the Food and Drug Administration for appro

Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 million Series A financing. Atlas Venture co-founded, seeded and incubated Vigil with late pre-clinical-stage assets in-licensed from Amgen Inc., who will remain a key shareholder in the company. The Series A round was co-led by Atlas Venture and Northpond Ventures and includes participating investors Hatteras Venture Partners and Alexandri

Amgen announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its investigational KRASG12C inhibitor, sotorasib, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation, as determined by an FDA-approved test, following at least one prior systemic therapy. "For more than 40 years, scientists have been trying to target KRAS. Today's news is a welcome update for

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)announced that it has entered into a strategic partnership and license option agreement with Lyon, FRANCE-based Amolyt Pharma (“Amolyt”), whereby both companies will work together to test and further optimize PeptiDream’s Growth Hormone Receptor Antagonist“GHRA” peptide candidates, with the goal of selecting a clinical candidate for development in acromegaly, a rare endoc

BridgeBio Pharma, Inc. and Maze Therapeutics announced the establishment of a joint venture, Contour Therapeutics, focused on transforming and advancing breakthrough precision medicine approaches designed to treat cardiovascular disease, the leading cause of death worldwide. This joint venture between two leading biotech companies unites Maze’s genetically driven approach to drug discovery, as well as insights from its COMPASS platform, with BridgeBio’s expertise in card

GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio. Initium Therapeutics is a US biotechnology company, a spin-off from South Korean biotech company Tiumbio, seeking antibody-based therapeutics for patients who are suffering from unaddressed incurable and rare diseases. The strategic collaboration between the two companies will allow Initium Therapeutics to e

ShapeTX, a next-generation gene therapy technology company with the industry's leading RNA targeting technology platform, today launches the AAVid ™ capsid discovery platform And announced the results in the first AAV5 variant library in a selection campaign for non-human primates. The AAVid ™ capsid discovery platform uses non-random mutant fitness to create a large library of billions of unique AAV variants, biology directly in vivo in non-human primates (NHPs). Re